Show simple item record

dc.contributor.authorQuinlan, Catherine
dc.contributor.authorBates, Marie
dc.contributor.authorCotter, Melanie
dc.contributor.authorRiordan, Michael
dc.contributor.authorWaldron, Mary
dc.contributor.authorAwan, Atif
dc.date.accessioned2012-08-27T07:58:38Z
dc.date.available2012-08-27T07:58:38Z
dc.date.issued2012-08-27
dc.identifier.citationTinzaparin is safe and effective in the management of hemodialysis catheter thrombosis., 58 (3):288-90 ASAIO J.en_GB
dc.identifier.issn1538-943X
dc.identifier.pmid22456106
dc.identifier.doi10.1097/MAT.0b013e31824c38c8
dc.identifier.urihttp://hdl.handle.net/10147/239991
dc.description.abstractChildren on hemodialysis are at increased risk of thrombosis, especially when dialyzed via a central venous catheter (CVC); there are limited published data regarding the safety and efficacy of tinzaparin in this group. We conducted a retrospective chart review of all children in the National Pediatric Hemodialysis Centre for Ireland diagnosed with a CVC thrombus and treated with subcutaneous tinzaparin over a 10 year period. Seven children were treated with subcutaneous tinzaparin for 10 CVC thrombi. Tinzaparin was commenced at 175 IU/kg/day and the dose was titrated by measuring anti-factor Xa levels, aiming for levels of 0.3-1.0 IU/ml. Treatment was continued until resolution of the CVC thrombus. Restoration of normal flows during dialysis occurred within 3 days in all patients. There were no episodes of bleeding and all children tolerated the treatment well.
dc.language.isoenen
dc.rightsArchived with thanks to ASAIO journal (American Society for Artificial Internal Organs : 1992)en_GB
dc.subject.meshAdolescent
dc.subject.meshCatheterization, Central Venous
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshDrug Monitoring
dc.subject.meshFibrinolytic Agents
dc.subject.meshHeparin, Low-Molecular-Weight
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshRenal Dialysis
dc.subject.meshThrombosis
dc.titleTinzaparin is safe and effective in the management of hemodialysis catheter thrombosis.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Nephrology, The Children's University Hospital, Dublin, Ireland. CathyQuinlan@mac.comen_GB
dc.identifier.journalASAIO journal (American Society for Artificial Internal Organs : 1992)en_GB
dc.description.provinceLeinsteren
html.description.abstractChildren on hemodialysis are at increased risk of thrombosis, especially when dialyzed via a central venous catheter (CVC); there are limited published data regarding the safety and efficacy of tinzaparin in this group. We conducted a retrospective chart review of all children in the National Pediatric Hemodialysis Centre for Ireland diagnosed with a CVC thrombus and treated with subcutaneous tinzaparin over a 10 year period. Seven children were treated with subcutaneous tinzaparin for 10 CVC thrombi. Tinzaparin was commenced at 175 IU/kg/day and the dose was titrated by measuring anti-factor Xa levels, aiming for levels of 0.3-1.0 IU/ml. Treatment was continued until resolution of the CVC thrombus. Restoration of normal flows during dialysis occurred within 3 days in all patients. There were no episodes of bleeding and all children tolerated the treatment well.


This item appears in the following Collection(s)

Show simple item record